Abstract:Background: Methylation plays a significant role in the etiology and pathogenesis of hepatocellular carcinoma (HCC). The aim of the present study is to identify aberrantly methylated-diferentially expressed genes (DEGs) and dysregulated pathways associated with the development of HCC through integrated analysis of gene expression and methylation microarray. Method: Aberrantly methylated-DEGs were identified from gene expression microarrays (GSE62232, GSE74656) and gene methylation microarrays (GSE44909, GSE57958). Functional enrichment and pathway enrichment analyses were performed through the database of DAVID. Protein-protein interaction (PPI) network was established by STRING and visualized in Cytoscape. Subsequently, overall survival (OS) analysis of hub genes was performed by OncoLnc. Finally, we validated the expression level of CDCA5 by quantitative real-time PCR (qRT-PCR) and western blotting, and performed Immunohistochemical experiments utilizing a tissue microarray. Cell growth assay and flow cytometry were behaved to explore the function of CDCA5. Results: Aberrantly methylated-DEGs were enriched in biological process, molecular function, cellular component and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. Among them, cell cycle was enriched most frequently, and some terms associated with cancer were enriched, such as p53 signaling pathway, pathways in cancers, PI3K-Akt signaling pathway and AMPK signaling pathway. After survival analysis and validation in TCGA database including methylation and gene expression status, 12 hub genes were identified. Furthermore, the expression level of new gene CDCA5 was validated in HCC cell lines and hepatic normal cell lines through qRT-PCR and western blotting. In additional, immunohistochemistry experiments revealed higher CDCA5 protein expression from HCC tumor tissues compared with paracancer tissues by tissue microarray. Finally, through loss of function, we demonstrated that CDCA5 promoted proliferation by regulating the cell cycle. Conclusions: In summary, the present study implied possible aberrantly methylated-differentially expressed genes and dysregulated pathways in HCC by bioinformatics analysis and experiments, which could be helpful in understanding the molecular mechanisms underlying the development and progression of HCC. Hub genes including CDC20, AURKB, BIRC5, RRM2, MCM2, PTTG1, CDKN2A, NEK2, CENPF, RACGAP1, GNA14 and especially the new gene CDCA5 may serve as biomarkers for diagnosis, treatment and prognosis of HCC.

Transcriptomic Analysis and Identification of Prognostic Biomarkers in Cholangiocarcinoma

Five Hub Genes Can Be the Potential DNA Methylation Biomarkers for Cholangiocarcinoma Using Bioinformatics Analysis

Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma

Molecular Profiling and Prognostic Analysis in Chinese Cholangiocarcinoma: an Observational, Retrospective Single-Center Study.

Survival analysis of genome-wide profiles coupled with Connectivity Map database mining to identify potential therapeutic targets for cholangiocarcinoma

Proteogenomic Characterization of Cholangiocarcinoma

Molecular profiling reveals potential targets in cholangiocarcinoma

Identification of Therapeutic Targets and Prognostic Biomarkers in Cholangiocarcinoma Via WGCNA.

Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma

Investigation of transcriptional and immunological disparities among patient groups with varied prognostic risk factors in cholangiocarcinoma

The construction of a prognostic model by apoptosis-related genes to predict survival, immune landscape, and medication in cholangiocarcinoma

Weighted Gene Coexpression Network Analysis Reveals Hub Genes Involved in Cholangiocarcinoma Progression and Prognosis

Characteristic Analysis of Featured Genes Associated with Cholangiocarcinoma Progression

Identification of prognostic biomarkers for cholangiocarcinoma by combined analysis of molecular characteristics of clinical MVI subtypes and molecular subtypes

Screening and Identification of Genes Associated with Cell Proliferation in Cholangiocarcinoma.

Aberrantly DNA Methylated-Differentially Expressed Genes and Pathways in Hepatocellular Carcinoma

Identification of Prognostic Gene Signature Associated with Tumor Microenvironment of Cholangiocarcinoma

Screening potential biomarkers of cholangiocarcinoma based on gene chip meta-analysis and small-sample experimental research

Specific Genomic Alterations and Prognostic Analysis of Perihilar Cholangiocarcinoma and Distal Cholangiocarcinoma.

Identifying Potential Prognostic Biomarkers Associated With Clinicopathologic Characteristics of Hepatocellular Carcinoma by Bioinformatics Analysis

Identification of Multiple Hub Genes and Pathways in Hepatocellular Carcinoma: A Bioinformatics Analysis